Source: Annual Congress 2003 - Resistance in adults and children
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
R. M. Gherasim, C. M. Pop, C. D. Zamora (Cluj-Napoca, Romania). The main causes which are responsible for secondary chemoresistance of Mycobacterium tuberculosis . Eur Respir J 2003; 22: Suppl. 45, 3266

Member's Comments

No comment yet.

Related content which might interest you: MDR tuberculosis as the principal cause of death Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006 Mycobacterium tuberculosis resistance Source: Eur Respir J 2002; 20: Suppl. 38, 360s Year: 2002 Importance of identifying Mycobacterium bovis as a causative agent of human tuberculosis Source: Eur Respir J 2010; 35: 692-694 Year: 2010 Discriminating active from latent tuberculosis by Mycobacterium tuberculosis (MTB)-peptide specific immunoresponses Source: Annual Congress 2008 - Priorities for tuberculosis research in Europe: discussing the results of the Tuberculosis Network European Trials Group (TBNET) Year: 2008 On the nature of Mycobacterium tuberculosis-latent bacilli Source: Eur Respir J 2004; 24: 1044-1051 Year: 2004 Risk factors for Mycobacterium tuberculosis infection among contacts of pulmonary tuberculosis patients Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I Year: 2012 Mycobacterium tuberculosis resistance profiles in index and secondary TB cases from the same household Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018 Clinical and laboratory features of Mycobacterium avium complex infection in comparison with infection, caused by Mycobacterium tuberculosis, in HIV-infected patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021 Year: 2022 The effects of drug resistance phenotype on proliferation of Mycobacterium tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004 Pulmonary tuberculosis with primary drug resistant mycobacterium tuberculosis -treatment outcomes Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004 Mycobacterium tuberculosis borderline rpoB mutations: emerging from the unknown Source: Eur Respir J, 58 (3) 2100783; 10.1183/13993003.00783-2021 Year: 2021 Drug resistance of Mycobacterium tuberculosis isolated from tuberculosis inflammatory foci Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005 Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies Source: Eur Respir J, 57 (4) 2004315; 10.1183/13993003.04315-2020 Year: 2021 Mycobacterium tuberculosis modulates mitochondrial function in human macrophages Source: Virtual Congress 2021 – Advanced in vitro models for drug discovery Year: 2021 Mycobacterium tuberculosis modulates mitochondrial function in human macrophages Source: Virtual Congress 2020 – Non-tuberculous mycobacteria and latent tuberculosis infection Year: 2020 Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis Source: Eur Respir J 2015; 46: 444-455 Year: 2015 The role of genexpert in the diagnosis of mycobacterium tuberculosis Source: International Congress 2019 – Tuberculosis: diagnosis Year: 2019 Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: 1092-1096 Year: 2005 Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020